Rongpeng Li | Molecular Biology | Research Excellence Award

Published on by Life Science

Dr. Rongpeng Li | Molecular Biology | Research Excellence Award

Nantong University | China

Dr. Rongpeng Li is a highly productive researcher whose scientific contributions span molecular microbiology, innate immunity, tumor biology, and therapeutic drug discovery. With a publication record of 60 Scopus-indexed documents, an h-index of 20, and 1541 citations, his work demonstrates sustained impact across both fundamental life science and translational biomedical research. He has led 7 completed or ongoing research projects, in addition to 6 industry-linked consultancy projects, highlighting his strong engagement with applied science. His research focuses on the molecular mechanisms by which the innate immune system recognizes pathogens, regulates virulence, and interacts with host defense pathways, contributing to new insights into immune regulation and pathogen evolution. He has also advanced the understanding of tumor proliferation, resistance mechanisms, CAR-T/CAR-M therapies, and the influence of the tumor and gut microbiome on cancer progression. His contributions to natural drug discovery include identifying new immune-modulating compounds and developing therapeutic vaccine strategies. Notably, his team discovered that TRIM7 promotes NAFLD/NASH progression through DUSP10 degradation, establishing a novel regulatory axis for metabolic liver disease and identifying a promising therapeutic target. With strong publication output, innovation in drug discovery, and leadership in interdisciplinary collaborations, Dr. Li stands as a significant contributor to contemporary life science research.

Profiles: Scopus | Orcid 

Featured Publications

Yan, F.-J., Ding, H., Zhang, N., Yan, S.-R., Huang, M.-X., Lu, J.-W., Wang, Y.-J., Yan, Y.-J., Li, R.-P., & Wang, Q. The E3 ligase tripartite motif 7 drives the progression of non-alcoholic fatty liver disease by targeting DUSP10 degradation in male mice.

Wang, Z., Zhao, J., He, S., Li, R., Wang, X., Yan, C., Zhao, J., & Wei, W.  Inorganic polyphosphate relieves ulcerative colitis by modulating the gut microbiota and metabolites.

Song, L., Wang, S., Zou, H., Yi, X., Jia, S., Li, R., & Song, J. Regulation of ergosterol biosynthesis in pathogenic fungi: Opportunities for therapeutic development. .

Song, J., Shi, L., Wang, S., Wang, Y., Zhu, Y., Jiang, J., & Li, R. Correction for Song et al., “Acidic/alkaline stress mediates responses to azole drugs and oxidative stress in Aspergillus fumigatus”.

Jeongyeon Mun | Molecular Biology | Best Researcher Award

Published on by Life Science

Dr. Jeongyeon Mun | Molecular Biology | Best Researcher Award

Columbia University Medical Center | South Korea

Jeong-Yeon Mun is a highly productive researcher whose scientific contributions demonstrate growing global impact, supported by 454 citations recorded in her publication list. Her Google Scholar profile shows an h-index of 17 and 19 peer-reviewed documents, reflecting a consistent record of influential research across cancer genomics, tumor microenvironment biology, and therapeutic resistance mechanisms. Mun’s work spans a diverse collection of studies published in high-visibility journals, where she has contributed as both first author and co-author on investigations addressing critical topics such as glioblastoma metabolism, chemoresistance in bladder cancer, molecular subtype identification, immune regulation, and biomarker discovery. Her research also extends into experimental oncology, employing advanced genomic, metabolic, and molecular techniques to uncover pathways that shape cancer progression and response to therapy. In addition to her publications, she is credited with multiple patents related to diagnostic biomarkers and genetic typing technologies, demonstrating translational relevance beyond academic settings. Mun’s growing citation impact underscores her role in shaping contemporary cancer biology, while her multidisciplinary expertise continues to support significant advancements in understanding tumor behavior, therapeutic vulnerabilities, and molecular disease mechanisms

Profile: Google Scholar

Featured Publications

Mun, J.-Y., Shu, C., Gao, Q., Akman, H. O., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. CDK12 regulates cellular metabolism to promote therapy resistance in glioblastoma. Cancer Research, 85(8_Supplement_1), 5395–5395.

Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J.-A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339.

Leem, S.-H., Mun, J.-Y., Jeong, M.-S., & Kim, M.-H., Yang, G.-E.  Novel biomarker for diagnosing and predicting metastasis or prognosis of various cancers, and use (U.S. Patent Application No. 18/573,338).

Nguyen, T. T. T., Gao, Q., Mun, J.-Y., Zhu, Z., Shu, C., Naim, A., Rogava, M., Izar, B., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. Suppressing PD-L1 expression via AURKA kinase inhibition enhances natural killer cell-mediated cytotoxicity against glioblastoma. Cells, 13(13), 1155.